Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Coddle Creek Capital LLC has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This prosecution involves 1 distinct examiner and 1 distinct art unit, indicating a very focused and singular effort at the patent office. The company's current workload is concentrated in one specific area, which suggests a targeted approach to its intellectual property development. This lack of diversification means all current resources are directed toward a single outcome.
The busiest examiner for the company is ALYSSA RAE STONEBRAKER, who is managing 1 busiest examiner pending office action. This action constitutes the total of 1 pending office action for the company. Therefore, the company's current prosecution success depends on the review conducted by this examiner. There are no other active matters to provide a buffer if this application faces significant hurdles.
The use of 1 distinct art unit reflects a narrow technical scope for the pending matter. Because there is only 1 distinct examiner, the company does not have to manage multiple examination styles at this time. Practitioners should prioritize the specific feedback from ALYSSA RAE STONEBRAKER to advance the 1 pending office action. Understanding the specific examination culture within the art unit is vital for a successful result.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STONEBRAKER, ALYSSA RAE | 1 | 58.3% | +49.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18482651 | SPIRAL STEROIDS AND PRECURSORS THEREOF FOR CLINICAL DIAGNOSIS AND TREATMENT OF NECROTIZING ENTEROCOLITIS AND PRE-ECLAMPSIA | STONEBRAKER, ALYSSA RAE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18482651 | SPIRAL STEROIDS AND PRECURSORS THEREOF FOR CLINICAL DIAGNOSIS AND TREATMENT OF NECROTIZING ENTEROCOLITIS AND PRE-ECLAMPSIA | STONEBRAKER, ALYSSA RAE | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18482651 | SPIRAL STEROIDS AND PRECURSORS THEREOF FOR CLINICAL DIAGNOSIS AND TREATMENT OF NECROTIZING ENTEROCOLITIS AND PRE-ECLAMPSIA | STONEBRAKER, ALYSSA RAE | 1627 | §103§112Other | Non-Final OA | — | Pending | Oct 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial